Sales of Biohaven's migraine tablet exceed expectations

Biohaven's tablet for preventive and acute treatment of episodic migraines has surpassed market expectations for the second quarter.
Photo: Kåre Viemose
Photo: Kåre Viemose
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

After Biohaven's migraine drug Nurtec ODT was approved for preventative treatment of episodic migraines in addition to its previous approval as an acute treatment, sales have exploded.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading